Author:
Mehra Niven,Dolling David,Sumanasuriya Semini,Christova Rossitza,Pope Lorna,Carreira Suzanne,Seed George,Yuan Wei,Goodall Jane,Hall Emma,Flohr Penny,Boysen Gunther,Bianchini Diletta,Sartor Oliver,Eisenberger Mario A.,Fizazi Karim,Oudard Stephane,Chadjaa Mustapha,Macé Sandrine,de Bono Johann S.
Reference33 articles.
1. GLOBOCAN 2012 v1.0, Cancer incidence and mortality worldwide: IARC cancer base no. 11;Ferlay,2016
2. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer;Tannock;N Engl J Med,2004
3. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer;Petrylak;N Engl J Med,2004
4. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial;de Bono;Lancet,2010
5. Long term efficacy and QOL data of chemohormonal therapy (C-HT) in low and high volume hormone naïve metastatic prostate cancer (PrCa): E3805 CHAARTED trial;Sweeney;Ann Oncol,2016
Cited by
103 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献